A Master Protocol To Evaluate The Long-Term Safety Of (LY3527727) Pirtobrutinib

Overview

About this study

The purpose of this study is to evaluate the long-term safety of pirtobrutinib.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Are participating in an eligible Lilly-sponsored clinical study evaluating pirtobrutinib

  • Are capable of giving signed informed consent

Exclusion Criteria:

  • Pregnant, or intend to become pregnant during the study, or within 30 days of last dose of study treatment or to breastfeed during the study or within 1 week of the last dose of study treatment

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 12/18/2024. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Yucai Wang, M.D., Ph.D.

Contact us for the latest status

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information

Publications

Publications are currently not available
.
CLS-20584904

Mayo Clinic Footer